Rv-Ny-Eso-1 Vaccine
Peritoneal Cavity Cancer
Ludwig Institute for Cancer ResearchvaccinePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
154 Active assets in the Peritoneal Cavity Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II GOG Foundation | Phase 3 | BBB |
Carboplatin University of Washington | Phase 3 | BBB |
Inno-206 Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | BBB |
Hycamtin Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | BBB |
PEGFILGRASTIM TORL Biotherapeutics, LLC | Phase 2/3 | BBB |
View all 50 →
Same molecule, other indications
Rv-Ny-Eso-1 Vaccine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →